A cluster-randomised study of the effect of albendazole treatment on the prevalence of childhood atopy among children with geohelminth infections

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN61195515

Enrollment

2730

Registered

2005-12-21

Start date

2002-06-15

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geohelminth infections Infections and Infestations Geohelminth

Interventions

Bimonthly albendazole (400 mg) for 12 months (total of seven treatments) versus no intervention.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schools: 1. Access during rainy season 2. Total size less than 150 children 3. Preliminary meetings attended by a majority of parents Individuals: 1. Healthy children in second to seventh year of primary education (i.e. aged eight to 14 years) 2. Informed written consent by a parent

Exclusion criteria

Exclusion criteria: Schools: 1. Limited access during rainy season 2. Total size more than 150 children 3. Preliminary meetings attended by minority of parents Individuals: 1. Children not in second to seventh year of primary education 2. No informed written consent by a parent

Design outcomes

Primary

Measure	Time frame
Atopy (measured by allergen skin test reactivity)	—

Secondary

Measure	Time frame
1. Allergic symptoms 2. Exercise-induced bronchospasm 3. Flexural dermatitis	—

Countries

Ecuador

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 11, 2026